Lunai Bioworks Strengthens European Strategy Through Restructuring
-
Israel detonates tunnel, strikes south Lebanon
-
Putin acknowledges fuel shortages after Ukraine strikes
-
Moriyasu praises 'united' Japan on eve of Brazil World Cup clash
-
Canada reach World Cup last 16 as late strike sinks South Africa
-
Looting, theft in Venezuela's earthquake zone add to tragedy
-
Perry stars as Australia knock India out of World Cup
-
Venezuela quakes kill 1,450, time running out to find survivors
-
Stokes 'content' after extraordinary England exit
-
West Indies beat Sri Lanka in first Test
-
Europe swelters as heatwave moves east
-
Asia's World Cup falls apart with just two teams remaining
-
Stokes announces shock England exit as New Zealand eye series win
-
Bromell upsets Lyles, Duplantis shines at Paris Diamond League
-
CAF president Motsepe hails African World Cup successes
-
Man Utd reveal Ugarte knee injury in Uruguay World Cup defeat
-
South Korea coach quits after early World Cup exit
-
Stokes out for 30 in final Test innings after shock England retirement
-
Venezuela quakes kill 1,400, time running out to find survivors
-
Wolff praises 'cold-blooded' Russell, enjoys Antonelli enthusiasm at Austrian GP
-
Hamilton laments lack of power and poor tyre performance
-
Stokes announces shock England exit as Mitchell bats New Zealand into commanding lead
-
Goals galore at record-breaking World Cup
-
Russell overcomes 'tricky run of form' to revive title bid
-
Augusta Tops Best Gold IRA Companies List By Gold Advisor
-
Europe swelters as heatwave moves east, excess deaths rise
-
They support Argentina at the World Cup, but are not Argentine
-
Raducanu hopes to feature at Wimbledon despite injury woe
-
Iran warns ships not to bypass its chosen Hormuz route
-
Russell holds off Verstappen to win Austrian Grand Prix
-
Serena blasts drug test rules ahead of Wimbledon return
-
England captain Stokes to retire from international cricket
-
Ogier wins Acropolis Rally to close in on Evans
-
South Africa maintain World Cup semi-final hopes with nervy win over Bangladesh
-
South Korea president apologises after World Cup group-stage exit
-
Japan's Ogura wins maiden MotoGP as Bezzecchi crashes in Assen
-
Bergs wins Eastbourne final to clinch first ATP title
-
Ravindra and Mitchell strengthen New Zealand's grip on England decider
-
Iran warns challenge to Hormuz routes will spike Middle East tensions
-
BIS warns 'pressure points' putting global economy at risk
-
From rubble to music: Gaza's Oud repairman
-
Ntamack aims to bring Toulouse Top 14 win 'energy' to Nations Championship campaign
-
Cycling industry bets on smart bikes to boost sales
-
'High-strung' camels race in Australian outback
-
In Idaho, the next generation of US nuclear reactors nears reality
-
Algeria and Austria reach World Cup knockouts after 3-3 thriller
-
Africa the winner of expanded World Cup amid mixed fortunes for minnows
-
DR Congo advance but Iran out as wild World Cup group stage wraps
-
Asia's vendors grapple with rising costs of ever-present plastics
-
Austria and Algeria reach World Cup knockouts after 3-3 thriller
-
Messi scores again as Argentina head into World Cup last 32 on a high
Lunai Bioworks Strengthens European Strategy Through Restructuring
Company remains committed to Europe with a streamlined, growth-focused approach.
LOS ANGELES, CALIFORNIA / ACCESS Newswire / September 8, 2025 / Lunai Bioworks Inc. (Nasdaq:RENB), an AI-powered drug discovery and biodefense company, today reaffirmed its long-term commitment to European markets and partnerships while announcing the elimination of its legacy subsidiary, Gedi Cube B.V., which has entered bankruptcy proceedings in the Netherlands.
"This allows us to move forward in Europe with a leaner, more focused model," said David Weinstein, Chief Executive Officer of Lunai Bioworks. "We remain deeply committed to building strategic collaborations across the continent and see significant opportunity to expand our AI-powered biodefense and drug discovery initiatives with new partners."
The restructuring of the European presence follows a comprehensive review of Lunai Bioworks' European business structure. The company emphasized that the bankruptcy of the subsidiary is not expected to have a material adverse impact on its ability to operate or pursue growth across Europe.
Key points for investors and stakeholders:
Streamlined Structure: Closing Gedi Cube B.V. eliminates legacy liabilities and simplifies European operations.
Focus on Growth Markets: Lunai Bioworks continues to prioritize partnerships with European pharma, biotech, and government agencies.
No Material Operational Impact: The bankruptcy is not expected to affect Lunai Bioworks' ability to deliver on global programs or partnerships.
Long-Term Commitment: Europe remains a key region in Lunai Bioworks' strategic roadmap, both for biodefense initiatives and therapeutic discovery collaborations.
By restructuring its European presence, Lunai Bioworks is aligning resources with its core mission - advancing safe and responsible AI for drug discovery and biodefense- while positioning for long-term growth in the region.
About Lunai Bioworks
Lunai Bioworks is an AI-powered drug discovery and biodefense company pioneering safe and responsible generative biology. With proprietary neurotoxicity datasets, advanced machine learning, and a focus on dual-use risk management, Lunai is redefining how artificial intelligence can accelerate therapeutic innovation while safeguarding society from emerging threats.
Media Contact:
David Weinstein
Chief Executive Officer
[email protected]
www.renovarogroup.com
SOURCE: Lunai Bioworks Inc.
View the original press release on ACCESS Newswire
A.Rodriguezv--AMWN
